• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Lantheus Holdings Inc.

    8/21/24 4:35:06 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LNTH alert in real time by email
    S-8 1 d881359ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on August 21, 2024

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM S–8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Lantheus Holdings, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   35-2318913

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

    201 Burlington Road, South Building

    Bedford, Massachusetts 01730

      01862
    (Address of Principal Executive Offices)   (Zip Code)

    Lantheus Holdings, Inc. 2015 Equity Incentive Plan

    (Full Title of Plan)

    Daniel Niedzwiecki

    Chief Administrative Officer and

    General Counsel

    201 Burlington Road, South Building

    Bedford, Massachusetts 01730

    (Name and address of agent for service)

    (978) 671-8648

    (Telephone number, including area code, of agent for service)

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large Accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    Lantheus Holdings, Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) to register an additional 4,000,000 shares of its common stock, par value $0.01 per share, that may be issued and sold under the Lantheus Holdings, Inc. 2015 Equity Incentive Plan, as amended (the “Plan”), following the amendment to the Plan that was approved by the Registrant’s stockholders at its annual meeting on April 25, 2024. This Registration Statement is submitted in accordance with General Instruction E to the Registration Statement on Form S-8 regarding registration of additional securities, and pursuant to that instruction, the contents of the Registration Statements on Form S-8 (File No.  333-205211, File No.  333-214343, File No.  333-220049, File No.  333-232919, File No.  333-258454 and File No. 333-264890) filed with the Securities and Exchange Commission on June 25, 2015, October 31, 2016, August 18, 2017, July 31, 2019, August 4, 2021 and May 12, 2022, respectively, are incorporated herein by reference.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.    Exhibits.

    See Exhibit Index below.


    EXHIBIT INDEX

     

              INCORPORATED BY REFERENCE
    EXHIBIT
    NUMBER
      

    DESCRIPTION OF EXHIBITS

       FORM      FILE
    NUMBER
         EXHIBIT     

    FILING

    DATE

    4.1    Amended and Restated Certificate of Incorporation of Lantheus Holdings, Inc.      8-K        001-36569        3.1      April 27, 2018
    4.2    Amended and Restated Bylaws of Lantheus Holdings, Inc.      8-K        001-36569        3.2      December 27, 2021
    4.3    Common Stock Certificate.      8-K        001-36569        4.1      June 30, 2015
    4.4    Lantheus Holdings, Inc. 2015 Equity Incentive Plan.      S-1/A        333-196998        10.37      June 16, 2015
    4.5    Form of 2015 Restricted Stock Agreement.      S-1/A        333-196998        10.38      June 16, 2015
    4.6    Form of 2015 Option Award Agreement.      S-1/A        333-196998        10.39      June 16, 2015
    4.7    Form of Restricted Stock Unit Award Agreement (Employee Time-Based Vesting).      10-Q        001-36569        10.2      April 29, 2022
    4.8    Form of Restricted Stock Unit Award Agreement (Relative Total Shareholder Return Performance-Based Vesting).      10-Q        001-36569        10.3      April 29, 2022
    4.9    Form of Stock Option Award Agreement (Time Vesting).      10-Q        001-36569        10.4      April 29, 2022
    4.10    Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan.      8-K        001-36569        10.1      April 28, 2016
    4.11    Second Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan.      8-K        001-36569        10.1      April 28, 2017
    4.12    Third Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan.      10-Q        001-36569        10.1      April 30, 2019
    4.13    Fourth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan.      8-K        001-36569        10.1      April 26, 2019
    4.14    Fifth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan.      8-K        001-36569        10.1      April 29, 2021
    4.15    Sixth Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan.      8-K        001-36569        10.1      May 2, 2022
    4.16    Seventh Amendment to Lantheus Holdings, Inc. 2015 Equity Incentive Plan      8-K        001-36569        10.1      April 29, 2024
    5.1*    Legal Opinion of Foley Hoag LLP.            
    23.1*    Consent of Independent Registered Public Accounting Firm, Deloitte & Touche LLP.            
    23.2*    Consent of Foley Hoag LLP (included as part of Exhibit 5.1).            
    24.1*    Power of Attorney (included as part of the signature page hereto).            
    107*    Filing Fee Table            

     

    * 

    Filed herewith


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933 the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bedford, Commonwealth of Massachusetts, on August 21, 2024.

     

    Lantheus Holdings, Inc.
    By:  

    /s/ Brian Markison

    Name:   Brian Markison
    Title:   Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Brian Markison, Robert J. Marshall, Jr. and Daniel Niedzwiecki, each acting alone, her or his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in her or his name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-8 (including all pre-effective and post-effective amendments and registration statements filed pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or her or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

      

    Title

      

    Date

    /s/ Brian Markison

    Brian Markison

      

    Chief Executive Officer and Director

    (Principal Executive Officer)

       August 21, 2024

    /s/ Robert J. Marshall, Jr.

    Robert J. Marshall, Jr.

      

    Chief Financial Officer

    (Principal Financial Officer)

       August 21, 2024

    /s/ Kimberly Brown

    Kimberly Brown

      

    Chief Accounting Officer

    (Principal Accounting Officer)

       August 21, 2024

    /s/ Mary Anne Heino

    Mary Anne Heino

       Chair of the Board of Directors    August 21, 2024

    /s/ Minnie Baylor-Henry

    Minnie Baylor-Henry

       Director    August 21, 2024

    /s/ Dr. Gérard Ber

    Dr. Gérard Ber

       Director    August 21, 2024

    /s/ Samuel Leno

    Samuel Leno

       Director    August 21, 2024

    /s/ Heinz Mäusli

    Heinz Mäusli

       Director    August 21, 2024


    /s/ Julie McHugh

    Julie McHugh

       Director    August 21, 2024

    /s/ Gary Pruden

    Gary Pruden

       Director    August 21, 2024

    /s/ Dr. James Thrall

    Dr. James Thrall

       Director    August 21, 2024
    Get the next $LNTH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNTH

    DatePrice TargetRatingAnalyst
    12/12/2025$80.00Hold → Buy
    Truist
    10/8/2025$77.00Buy → Neutral
    Goldman
    8/12/2025$63.00Buy → Hold
    Truist
    12/18/2024$143.00Buy
    Goldman
    9/3/2024$175.00Buy
    Redburn Atlantic
    7/10/2024$100.00 → $130.00Mkt Outperform
    JMP Securities
    12/18/2023Outperform → Mkt Perform
    William Blair
    12/4/2023$100.00Outperform
    TD Cowen
    More analyst ratings

    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

    3/8/24 11:24:53 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 26, 2026, to discuss its financial and operating results for the fourth quarter and full year of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    2/12/26 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies

    BEDFORD, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced it has completed the previously announced sale of its single photon emission computed tomography (SPECT) business to SHINE Technologies, LLC, a subsidiary of Illuminated Holdings, Inc. (collectively, "SHINE"). Under the terms of the agreement, SHINE has acquired Lantheus' SPECT business, including its diagnostic agents (TechneLite® (Technetium Tc 99m generator), NEUROLITE® (Kit for the Preparation of Technetium

    1/2/26 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus to Present Florbetaben F 18 Data at CTAD 2025

    BEDFORD, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced the presentation of new florbetaben F18 data at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) 2025 conference, taking place December 1-4, in San Diego, CA. Presentation details are as follows: Poster Presentation Date & Time: Wednesday, December 3, 2025; 7:15 AM – 5:30 PM PT Session Number: 06 Session Title: Clinical Trials: Imaging Poster Title: Florbetaben binding to amyloid plaques is unaffected by amyloid-ta

    11/24/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lantheus Holdings upgraded by Truist with a new price target

    Truist upgraded Lantheus Holdings from Hold to Buy and set a new price target of $80.00

    12/12/25 8:36:54 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Holdings downgraded by Goldman with a new price target

    Goldman downgraded Lantheus Holdings from Buy to Neutral and set a new price target of $77.00

    10/8/25 8:24:33 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Holdings downgraded by Truist with a new price target

    Truist downgraded Lantheus Holdings from Buy to Hold and set a new price target of $63.00

    8/12/25 7:56:11 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

    SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    2/12/26 12:50:04 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

    SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    2/5/26 2:59:24 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 144 filed by Lantheus Holdings Inc.

    144 - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/26/25 10:43:53 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Morgan Amanda Michelle covered exercise/tax liability with 724 shares, increasing direct ownership by 54% to 39,094 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    12/17/25 4:15:34 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Executive Chair Heino Mary Anne was granted 14,285 shares, increasing direct ownership by 4% to 332,935 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    11/19/25 5:52:58 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    CFO and Treasurer Marshall Robert J. Jr. covered exercise/tax liability with 727 shares, decreasing direct ownership by 0.82% to 88,133 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    9/3/25 4:29:54 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Leadership Updates

    Live Leadership Updates

    View All

    Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

    BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. "We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus," said Brian Markison, CEO of Lantheus. "Ludger's proven leadership, scientific

    7/22/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

    BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i

    1/30/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Financials

    Live finance-specific insights

    View All

    Lantheus to Host Fourth Quarter and Full Year 2025 Earnings Conference Call and Webcast on February 26, 2026, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, February 26, 2026, to discuss its financial and operating results for the fourth quarter and full year of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    2/12/26 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update

    Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings per share of $1.27 and free cash flow of $94.7 millionSeparately announced upcoming retirement of CEO, departure of President and appointment of prior CEO to Executive Chairperson; Board conducting CEO searchAnnounced PDUFA dates for its new formulation of piflufolastat F 18 PSMA PET imaging agent; for MK-6240, its F 18 tau-targeted positron emission tomography (PET) imaging agent; and for LNTH-2501, its Ga 68 PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs)Closed acquisition of Life Molecular

    11/6/25 7:02:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025, to discuss its financial results and provide a business update for the third quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    10/23/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

    SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 3:29:28 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    2/14/24 1:18:20 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care